Impiricus

New whitepaper..... When reviewing your marketing tactics, does the activity seem more multichannel than omnichannel? According to many HCPs, that is the case with many pharma brands. Why? Perhaps it is because many brand initiatives are focused on a select number of publications, websites, and closed "doctor-only" social media apps. HCPs operate outside these ecosystems. When they need your valuable resources, you want to be there for them. When HCPs need fingertip access to your message and support, we help you be present where and when they need you most. #omnichannel #pharmamarketing #hcpengagement #impiricus

Excited to have shared insights at #MASSWest on Navigating the Path to Omnichannel Integration in Medical Affairs 🎤 Leveraging data 📊 and creating a seamless omnichannel experience 🌐 is key to transforming how we engage with HCPs. It was a pleasure to share the stage with Shivani Desai, Ajit Kulkarni, PhD MBA, and Sandy Donaldson — together, we unpacked strategies to transform medical communications, optimize engagement, and drive meaningful connections across every touchpoint💡🤝 A huge thanks to everyone at the summit for the thought-provoking discussions. Let’s continue pushing boundaries in #MedicalAffairs 🚀 #OmnichannelIntegration #DataDrivenStrategies #Leadership #Collaboration #FiercePharma #MASSWest2024

We are excited to announce Adam Derengowski has joined the Impiricus team as SVP Sales Operations. Adam brings world class experience in Digital Marketing, Business Development and Sales Leadership within the Pharmaceutical, Biotechnology, Medtech and Healthcare Industries. 

Our innovative audio approach to reaching healthcare professionals just earned top honors! Our "Pioneering Audio Outreach to HCPs" campaign snagged the Impiricus HCP Impact Award at the Fierce Pharma Marketing Awards. What makes this victory even sweeter? The judges who recognized our impact were the same audience we crafted the campaign for! https://lnkd.in/eeWe3j3a

When Dr Osama Hashmi and I created Impiricus in 2021, we knew we were going to disrupt the Pharma industry, but we didn't know exactly how. Our thesis was that Pharma would continue to increase digital interactions with HCPs. However, with traditional solutions and channels, this would only increase white noise for HCPs. A new approach was needed to leverage technology and the power of integrating HCPs into every aspect of design. Not just a new channel but a new AI and data-driven methodology that would simultaneously increase HCP access, engagement, and trust. Fast-forward three years, and today, Impiricus is the trusted partner between HCPs and the world's leading Pharma companies. Our platform connects HCPs in their preferred channel to the most relevant information for patient impact. And we are just getting started.... In the coming weeks and months, we will announce fundamental new channels, capabilities, and partnerships that will change how our industry thinks about HCP engagement. Stay tuned!

Very interesting insights from Drs. Haque and Firozvi on how pharma can help them better! #DPEast #DigitalPharmaSeries

The HCPs perspective. Great session led in expert fashion by Sandy Donaldson from Impiricus where two very busy practicing MDs shared insights around their optimal experiences and interactions with pharma companies. They both shared the following ideal world scenario. (Paraphrasing here for brevity.) “I want to recieve content where, when and in the format I want.” “Provide me concise content in consumable formats that I can access on a phone or iPad when I need it.” “We want relationships with our pharma reps. We need them.” “The pharma companies that consistently deliver value are rewarded with more access, engagement and business.” Of course, me and Mobile Locker loved that answer since these things are exactly what we help our pharma clients deliver to their HCP targets. Seek first to provide value. The rest will follow. #DPEAST #pharmamarketing

I’m proud to be hosting a fireside chat at Digital Pharma East featuring practicing doctors. I’m looking forward to asking Dr. Adel Haque and Dr. Kashif Ferozvi why HCP engagement is flatlining and how Pharma can resuscitate the model. *What is the disconnect between how pharma engages with you now vs. how you run your practice? *How can pharma actually help you do your job? *Which pharma companies ‘actually’ help you help your patients? Independent doctors need to be involved in pharma so they can give physicians and their patients what they actually need. Pharma spends over $15 billion a year marketing to doctors, yet it doesn’t always get their perspective or take it seriously enough. We also sponsored a pharma marketing award that is the only one judged by doctors. We received about 20 submissions and the judges recently narrowed it down to five finalists. The fireside chat is Sept. 11 in Philadelphia, where the award winners will also be announced (link for more details in comments). It’s part of the annual four-day conference that is usually a place for pharma and marketing folks to share ideas, so I think it’s valuable to hear from the medical profession. What else do you want me to ask?

We are looking forward to joining Fierce Pharma at the Digital Pharma East event on September 9-12th. Hear our CEO and Co-Founder Sandy Donaldson, live with Dr Kashif Firozvi (Onc) and Dr Adel Haque (Derm), discuss why HCP engagement is flatlining and how Pharma can resuscitate the model. Join us and the finalists of the Impiricus HCP Impact Award as we announce the winner on stage at the Fierce Pharma Marketing Awards Gala. Schedule time to meet us at our Meeting Suite by the puppy park. #DPE #Pharma

A major change is coming for pharma companies and seniors alike: The price of 10 blockbuster drugs will soon drop, and many more will follow. The 2022 Inflation Reduction Act allowed Medicare to negotiate drug prices directly with big pharma for the first time, starting with 10 drugs in 2026 and expanding with 15-20 additional drugs each year. The first crop of Part D drugs are used by 9 million seniors who can pay over $10,000 for some of the prescriptions. The discounts range from 38% to 79% off the list price. At the top of the list is the blood thinner Eliquis, from Pfizer and Bristol Myers Squibb. Analysts are already nervous the upcoming changes could impact the companies’ bottom line, though the full impact won’t be known until price caps are announced in the coming months. The government expects savings of about $25 billion a year by 2031, starting with $6 billion in savings in 2026, so it will be a sea change for big pharma. Other affected companies include Merck, Johnson & Johnson, AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Novartis. As years go on and more Part D and Part B drugs are added to the program, virtually every drugmaker and nearly all 65 million Medicare members (which also includes younger people on disabilities) will be affected. Already, 1 in 7 seniors don’t fill prescriptions because of high costs. The retail prices charged for the first 10 drugs affected are 3-8x more expensive in the U.S. than in comparable countries. On the other side are drug companies that do not believe the program is even legal. Big pharma has already sued to block the program and continues to fight tooth and nail to do so. A lower-court judge rejected the suit but it was just appealed and it’s possible it ends up in the U.S. Supreme Court. It’s worth noting some of the affected drugs are likely to face competition soon as their patents expire - which could have an even bigger impact on pricing than the Medicare negotiations. Drugs that bring in a whopping $236 billion in annual revenue are set to lose their exclusivity by the end of this decade. See the first link in the comments for more info on that.